Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations; Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- PMID: 30338958
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations; Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Erratum for
-
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.N Engl J Med. 2015 Aug 20;373(8):726-36. doi: 10.1056/NEJMoa1502309. N Engl J Med. 2015. PMID: 26287849 Free PMC article. Clinical Trial.
-
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. N Engl J Med. 2017. PMID: 28581356 Free PMC article. Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous